Pharmaessentia Corp. Advances with Phase III Clinical Trial for P1101 Targeting Pre-fibrotic/Early PMF

On January 3, 2025, PharmaEssentia Corp. announced the submission of a Phase III clinical trial protocol for Ropeginterferon alfa-2b (P1101) to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). This trial is aimed at adult patients suffering from pre-fibrotic/early primary myelofibrosis or overt primary myelofibrosis at low or intermediate-1 risk, as classified by the Dynamic International Prognostic Scoring System Plus (DIPSS Plus).

This submission represents a significant milestone in the development of P1101, with the company planning to seek marketing authorization post-trial. The trial is a component of the multinational, multicenter global study known as HOPE-PMF. Notably, Ropeginterferon alfa-2b has already received approval for the treatment of Polycythemia Vera (PV) in nearly 40 countries, including major markets like the United States, Japan, China, and the European Union.

The announcement underscores the potential market impact and the strategic importance of this phase in the drug's development. However, specific financial details have not been disclosed to safeguard the interests of the company and its investors. PharmaEssentia Corp. has also advised investors to exercise caution due to the inherent risks and uncertainties associated with new drug development.